Profile data is unavailable for this security.
About the company
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-142.66m
- Incorporated2016
- Employees143.00
- LocationAdicet Bio Inc200 BERKELEY STREET, 19TH FLOORBOSTON 02116United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (302) 655-5049
- Websitehttps://www.adicetbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inotiv Inc | 585.17m | -33.21m | 107.29m | 1.96k | -- | 0.4221 | 4.90 | 0.1834 | -1.29 | -1.29 | 22.73 | 9.85 | 0.6858 | 6.46 | 7.12 | 299,320.70 | -3.96 | -23.84 | -4.62 | -29.26 | 30.29 | 29.31 | -5.78 | -33.24 | 1.28 | 0.1431 | 0.5988 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Cellectar Biosciences Inc | 0.00 | -37.98m | 107.75m | 20.00 | -- | -- | -- | -- | -3.20 | -3.20 | 0.00 | -0.0654 | 0.00 | -- | -- | 0.00 | -225.65 | -83.69 | -499.83 | -99.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Sangamo Therapeutics Inc | 176.23m | -257.83m | 108.31m | 405.00 | -- | 1.12 | -- | 0.6146 | -1.46 | -1.46 | 1.01 | 0.4653 | 0.4843 | -- | 76.61 | 435,140.80 | -70.85 | -26.09 | -90.72 | -31.04 | -- | -- | -146.30 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| aTyr Pharma Inc | 353.00k | -50.39m | 108.71m | 56.00 | -- | 1.12 | -- | 307.95 | -0.9537 | -0.9537 | 0.0066 | 1.43 | 0.0033 | -- | 0.0497 | 6,303.57 | -46.57 | -45.45 | -54.04 | -52.74 | -- | -- | -14,276.77 | -784.19 | -- | -- | 0.0208 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| GlycoMimetics Inc | 10.00k | -36.90m | 110.85m | 35.00 | -- | 2.88 | -- | 11,085.47 | -0.5841 | -0.5841 | 0.0002 | 0.5966 | 0.0002 | -- | 0.0625 | 285.71 | -75.98 | -43.60 | -90.65 | -47.82 | -- | -- | -368,994.20 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 111.34m | 84.00 | -- | 7.28 | -- | 31.81 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Relmada Therapeutics Inc | 0.00 | -98.79m | 112.25m | 20.00 | -- | 1.31 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| FibroGen Inc | 147.75m | -284.23m | 112.41m | 486.00 | -- | -- | -- | 0.7608 | -2.93 | -2.93 | 1.52 | -2.07 | 0.2859 | 0.4597 | 6.28 | 304,016.50 | -55.51 | -30.62 | -119.42 | -42.31 | 87.24 | 93.52 | -194.16 | -119.08 | 1.33 | -53.30 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Hongchang International Co Ltd | 2.68m | -378.79k | 115.49m | 8.00 | -- | 2.85 | -- | 43.16 | -0.0009 | -0.0009 | 0.0071 | 0.078 | 0.1065 | -- | 2.78 | -- | -1.51 | -7.98 | -1.60 | -10.94 | 2.59 | 11.47 | -14.16 | -64.88 | 3.74 | -- | 0.1417 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -142.66m | 115.86m | 143.00 | -- | 0.3585 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Rezolute Inc | 0.00 | -56.83m | 119.18m | 51.00 | -- | 1.28 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 119.18m | 37.00 | -- | 0.9667 | -- | 114.34 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| Immunic Inc | 0.00 | -93.61m | 119.81m | 77.00 | -- | 2.08 | -- | -- | -2.11 | -2.11 | 0.00 | 0.6404 | 0.00 | -- | -- | 0.00 | -102.84 | -72.09 | -129.79 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 120.06m | 168.00 | -- | 0.7928 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -81.41m | 121.29m | 54.00 | -- | 1.35 | -- | -- | -5.11 | -5.11 | 0.00 | 2.35 | 0.00 | -- | -- | 0.00 | -113.72 | -80.06 | -136.52 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -22.26m | 124.19m | 13.00 | -- | 9.65 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Adicet Bio Inc's reporting currency: US Dollar USD
35.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 25 Jan 2024 | 6.14m | 7.47% |
| Commodore Capital LPas of 10 Jan 2024 | 4.25m | 5.17% |
| RTW Investments LPas of 31 Dec 2023 | 4.13m | 5.03% |
| Millennium Management LLCas of 23 Feb 2024 | 3.95m | 4.80% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.78m | 3.38% |
| Cowen & Co. LLCas of 31 Dec 2023 | 2.72m | 3.31% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.01m | 2.45% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.66m | 2.02% |
| Tang Capital Management LLCas of 31 Dec 2023 | 876.35k | 1.07% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 766.60k | 0.93% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
